Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
PARSIPPANY, N.J., Sept. 13, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc.  (Nasdaq: PCRX ), an emerging specialty pharmaceutical company, today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the UBS Global Life Sciences Conference on Tuesday, September 20, 2011, at 11 a.m. EDT to be held at the Grand Hyatt New York Hotel & Conference Center in New York City. Mr. Stack is expected to present an overview of the company.
A live audio webcast of the Pacira presentation can be accessed by visiting the "Investors & Media" section of the company's website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
Pacira Pharmaceuticals, Inc. is an emerging specialty
pharmaceutical company focused on the development, manufacture and
commercialization of novel pharmaceutical products, based on its
proprietary DepoFoam drug delivery technology, for use in hospitals
and ambulatory surgery centers. In December 2010, Pacira announced
that its New Drug Application (NDA) for EXPAREL, the company's most
advanced investigational product candidate, had been accepted for
filing by the U.S. Food and Drug Administration (FDA). The FDA has
assigned a Prescription Drug User Fee Act (PDUFA) goal date of
October 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a
bupivacaine-based product and has completed extensive Phase 3
clinical development for postsurgical analgesia by infiltration.
EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is
designed to address the limitations of widely used medications by
enhancing their dosing and/or administration profile. Additional
information about Pacira is available at www.paci